Niflumic acid

Chemical formula: C₁₃H₉F₃N₂O₂  Molecular mass: 282.218 g/mol  PubChem compound: 4488

Interactions

Niflumic acid interacts in the following cases:

Other non-steroidal anti-inflammatory drugs (NSAIDs)

Non steroidal anti-inflammatory drugs (NSAIDS)

Selective serotonin reuptake inhibitors (SSRIs)

Mild to moderate renal impairment

In patients with mild to moderate renal impairment, close monitoring of renal function and the use of the lowest effective dose are recommended.

Mild to moderate hepatic impairment

In patients with mild to moderate hepatic impairment, close monitoring of hepatic function and the use of the lowest effective dose are recommended.

Oral thrombolytics

Oral anticoagulants (such as warfarin), unfractionated heparin, low-molecular-weight heparins, and related products: there is an increased risk of bleeding due to the inhibition of platelet function and damage to the gastroduodenal mucosa caused by NSAIDs. If this combination of medications cannot be avoided, close clinical and laboratory monitoring is required.

Antihypertensive agents

Antihypertensive agents (such as beta-blockers, ACE inhibitors, and diuretics): a reduced antihypertensive effect may be observed, as NSAIDs inhibit vasodilatory prostaglandins.

Diuretics

There is a risk of acute renal failure in dehydrated patients due to a reduction in glomerular filtration, which results from decreased synthesis of renal prostaglandins. At the start of treatment, patients should be hydrated, and renal function should be monitored.

Medications that can cause hyperkalemia

at least one of
Potassium-sparing agents
ACE inhibitors, plain
Angiotensin II antagonists, plain
Heparin group
Ciclosporin
Tacrolimus
Trimethoprim
Non steroidal anti-inflammatory drugs (NSAIDS)

Lithium

Lithium (a risk associated with several NSAIDs): Blood lithium levels increase and may reach toxic concentrations due to reduced renal excretion of lithium. If this combination cannot be avoided, blood lithium levels should be closely monitored, and the lithium dosage must be adjusted during the course of treatment with the combination of the two drugs, as well as following the discontinuation of the NSAID.

Fertility

Prostaglandin synthesis inhibitors, including niflumic acid, may impair female fertility and are not recommended for women attempting to conceive. Discontinuation of niflumic acid therapy should be considered in women who are taking niflumic acid and are experiencing difficulty conceiving or are undergoing investigation for infertility.

Oral glucocorticosteroids

at least one of
Betamethasone
Dexamethasone
Fluocortolone
Methylprednisolone
Paramethasone
Prednisolone
Prednisone
Triamcinolone
Hydrocortisone
Cortisone
Deflazacort
Prednylidene

High-dose methotrexate

Methotrexate, at high doses (15 mg/week or more): an increase in the hematological toxicity of methotrexate is observed due to a reduction in renal clearance. If the combination cannot be avoided, renal function must be closely monitored.

Low-dose methotrexate

Methotrexate

Pentoxifylline

There is an increased risk of bleeding. Closer clinical monitoring and more frequent checks of the bleeding time are required.

Ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, iloprost

Other antiplatelet agents such as ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, and iloprost: there is an increased risk of gastrointestinal ulceration and bleeding due to an additive synergistic effect. If this combination cannot be avoided, close clinical and laboratory monitoring is required, including monitoring of the bleeding time.

Zidovudine

There is a risk of increased toxicity affecting the erythroid lineage due to an effect on reticulocytes, potentially leading to severe anemia, which may manifest 8 days after the initiation of NSAID therapy. A complete blood count, differential count, and reticulocyte count should be monitored 8–15 days after starting NSAID treatment.

Asthma

Niflumic acid should be used with caution in patients with pre-existing asthma. Asthmatic patients with chronic rhinitis, chronic rhinosinusitis, and/or nasal polyps are at an increased risk of bronchospasm and anaphylaxis when taking NSAIDs, including niflumic acid.

Intrauterine contraceptive device (IUDs)

Intrauterine contraceptive device

Patients with cardiovascular and cerebrovascular risk factors

Clinical studies and epidemiological data suggest that the use of certain NSAIDs may be associated with an increased risk of arterial thrombotic events (e.g., myocardial infarction or stroke), which can be fatal. The risk of arterial thrombotic events increases with high doses and long-term treatment, and has been associated with both COX-2 selective and non-selective NSAIDs.

Consequently, patients with uncontrolled hypertension, congestive heart failure, established coronary heart disease, peripheral arterial disease, and/or cerebrovascular disease should be treated with niflumic acid only after careful consideration of the risk-benefit profile for the individual patient.

Niflumic acid should be administered with caution to patients with a history of hypertension and/or heart failure. Fluid retention and edema have been reported in association with NSAID treatment; these may lead to the onset of hypertension or the worsening of pre-existing hypertension, as well as an increased risk of adverse cardiovascular events. Blood pressure should be closely monitored at the initiation of treatment and throughout its course. Patients should be informed about the signs of serious cardiovascular adverse events (e.g., angina, dyspnea, weakness, difficulty speaking) and the steps to take should these occur.

Caution should be exercised regarding the use of niflumic acid in patients undergoing coronary artery bypass graft (CABG) surgery, or immediately before or after heart surgery, with particular attention paid to concomitant medications.

Infections

Niflumic acid should be used with caution in patients with an active infection or at risk of infection, even if the infection is well controlled, as treatment with niflumic acid may mask the signs and symptoms of the infection.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈